Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02023346 · ClinicalTrials.gov registry record
Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
A clinical trial of Malignant Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 95
- Enrollment target
- 1
- Study location
NCT02023346: Completed study of Malignant Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02023346 is a study of Malignant Glioma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 95 participants, roughly in line with the 90-participant average among 40 other Malignant Glioma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02023346, a study of Malignant Glioma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about the understanding patients with brain tumors have of their disease and their communication with their physician. Ultimately, we hope to use these findings to improve communication between patients and their doctors.
Conditions Studied
Interventions
- BEHAVIORAL surveys and cognitive tests
Study Locations (1)
New York
- Memoral Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2013-12 |
| Est. Completion | 2018-10-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02023346
The ClinicalTrials.gov registry entry for NCT02023346 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 90-participant average among 40 other Malignant Glioma trials with a reported enrollment target. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 1 intervention - of which surveys and cognitive tests is the first listed.
NCT02023346 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02023346 about?
NCT02023346 is a clinical study titled "Prognostic Awareness and Patient-Physician Communication in Malignant Glioma". The purpose of this study is to learn more about the understanding patients with brain tumors have of their disease and their communication with their physician. Ultimately, we hope to use these findings to improve communication between patients and their doctors.
What is the current status of trial NCT02023346?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2013-12. Estimated completion is 2018-10-30.
What conditions does trial NCT02023346 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT02023346?
The interventions under investigation include: surveys and cognitive tests (BEHAVIORAL).
Who is sponsoring clinical trial NCT02023346?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02023346 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mapping of Electrical Properties in the Brain
RECRUITING
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
RECRUITING
-
Fitness and Nutrition in Glioma
RECRUITING · NA
-
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
RECRUITING · Phase 1
-
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.